• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Yanni Barbara

    6/24/22 6:57:39 AM ET
    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ONCR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Yanni Barbara

    (Last) (First) (Middle)
    C/O ONCORUS, INC.
    50 HAMPSHIRE STREET, SUITE 401

    (Street)
    CAMBRIDGE MA 02139

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Oncorus, Inc. [ ONCR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/23/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $1.6 06/23/2022 A 12,500 (1) 06/23/2032 Common Stock 12,500 $0.00 12,500 D
    Explanation of Responses:
    1. The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date.
    Remarks:
    /s/ Brian J. Shea, Attorney-in-Fact 06/24/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ONCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONCR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Oncorus Inc.

      DEFA14A - Oncorus, Inc. (0001671818) (Filer)

      8/7/23 6:52:07 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by Oncorus Inc.

      15-12G - Oncorus, Inc. (0001671818) (Filer)

      8/3/23 5:00:26 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Oncorus Inc.

      DEFA14A - Oncorus, Inc. (0001671818) (Filer)

      7/28/23 4:40:36 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Oncorus with a new price target

      Maxim Group initiated coverage of Oncorus with a rating of Buy and set a new price target of $35.00

      3/16/21 7:41:50 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Shea Brian J. claimed ownership of 8,541 shares

      3 - Oncorus, Inc. (0001671818) (Issuer)

      6/16/23 9:20:42 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Nolte Alexander

      3 - Oncorus, Inc. (0001671818) (Issuer)

      5/22/23 5:00:27 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Flynn James E sold $88,254 worth of shares (336,235 units at $0.26)

      4 - Oncorus, Inc. (0001671818) (Issuer)

      12/30/22 7:16:31 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Oncorus Inc. (Amendment)

      SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

      2/14/23 8:02:36 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Oncorus Inc. (Amendment)

      SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

      2/13/23 12:36:32 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Oncorus Inc. (Amendment)

      SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

      2/2/23 2:15:07 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

      IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

      5/22/23 4:05:00 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Appoints Douglas Fambrough to Board of Directors

      -Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors. "We are thrilled to welcome Doug to our board and leverage his significant expertise and executive leadership skills as we work to advance our next-generation HSV and selectively self-amplifying vRNA/LNP platforms," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer

      6/23/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer

      CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Richard Wanstall as Chief Financial Officer. "We are pleased to welcome Rick as our Chief Financial Officer and we look forward to drawing from his notable experience leading biotech companies through significant organizational growth," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "Rick is a trusted colleague that I, as well as other members of the senior leadership team, have had the pleasure of working alongside in our previ

      5/10/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncorus Announces Workforce Reduction Plan

      ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company's board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus' workforce, which is expected to be completed by August 2023. Theodore (Ted) Ashburn, M.D., Ph.D. (Chief Executive Officer), Stephen W. Harbin (C

      6/1/23 4:05:00 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

      IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

      5/22/23 4:05:00 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

      Research collaboration leverages Oncorus' proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong's mRNA expertiseOpportunity for future license, manufacturing and supply agreement for formulated drug candidates ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle

      1/4/23 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Financials

    Live finance-specific insights

    See more
    • Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

      Company now focused on the development of ONCR-021, Oncorus' lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being discontinuedPrioritization of ONCR-021 and reduction in workforce reduces company's cash burn rate; Oncorus reiterates guidance of cash runway into early 2024 ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeli

      11/30/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

      Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021Signed exclusive licensing agreement with Gaeta Therapeutics for use of locally delivered IL-12 via oncolytic viral expression in combination with immune checkpoint inhibitorsAdditional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Continued to advance preclinical programs, including ONCR-021 towards IND filing in mid-2023Strengthened executive leadership team with promotion of John Goldberg, M.D., to Chief Medical Office

      3/9/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021

      ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, injectable solid tumorsRecommended Phase 2 dose (RP2D) selected and expansion monotherapy cohort dosing is underwayThree of eight evaluable patients at RP2D across multiple indications (cutaneous melanoma, head and neck cancer, and mucosal melanoma) experienced clinical benefit after two doses of single-agent ONCR-177Proof of principle established for propriety Herpes Simplex Virus (HSV) platform that leverages microRNA attenuation to enable interferon resistance via retention of γ34.5 and five complementary immunomo

      11/12/21 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care